Actively Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Led by ArriVent BioPharma, Inc. · Updated on 2026-02-17
405
Participants Needed
15
Research Sites
279 weeks
Total Duration
On this page
Sponsors
A
ArriVent BioPharma, Inc.
Lead Sponsor
L
Lepu Biopharma Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
CONDITIONS
Official Title
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to sign the informed consent form and follow study requirements
You will not qualify if you...
- Patients with more than one cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
ULCA
Los Angeles, California, United States, 90095
Not Yet Recruiting
2
UCSF
San Francisco, California, United States, 94158
Not Yet Recruiting
3
University of Colorado
Aurora, Colorado, United States, 80010
Not Yet Recruiting
4
Sarah Cannon Research Institute
Denver, Colorado, United States, 80218
Not Yet Recruiting
5
Sarah Cannon Research Institute
Sarasota, Florida, United States, 34232
Not Yet Recruiting
6
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Not Yet Recruiting
7
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Not Yet Recruiting
8
NEXT Dallas
Irving, Texas, United States, 75039
Not Yet Recruiting
9
NEXT Virginia
Fairfax, Virginia, United States, 22031
Not Yet Recruiting
10
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Not Yet Recruiting
11
Peking University Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
12
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Active, Not Recruiting
13
Hunan Cancer Hospital
Changsha, Hunan, China
Active, Not Recruiting
14
Renji Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Actively Recruiting
15
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
P
Program Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here